Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level

Vascular Health and Risk Management

Volumn 2, Issue 4, 2006, Pages 507-514

  Roccatagliata, Daria ^a   Avanzini, Fausto ^a   Monesi, Lara ^a   Caimi, Vittorio ^b   Lauri, Davide ^a   Longoni, Paolo ^c   Marchioli, Roberto ^d   Tombesi, Massimo ^b   Tognoni, Gianni ^a   Roncaglioni, Maria Carla ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CSeRMEG Centro Studi e Ricerca in Medicina Generale   (Italy)

^c CoS Consorzio Sanità ^*  (Italy)

^d Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Diabetes; General practice; Global cardiovascular risk; Hyperlipideamia; Hypertension

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIGUANIDE DERIVATIVE; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SULFONYLUREA;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENERAL PRACTITIONER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MONOTHERAPY; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; ITALY; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33846919426     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.4.507     Document Type: Article

References (28)

1. Amar J, Vaur L, Perret M, et al. on behalf of the PRATIK Study investigators. 2002. Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK Study). J Hypertens, 20:779-84.
2. Ansell BJ, Watson KE, Fogelman AM. 1999. An evidence-based assessment of the NCEP adult treatment panel II guidelines. JAMA, 282:2051-57.
3. Avanzini F, Alli C, Colombo P, et al. on behalf of the Physicians taking part in STAP. 1998. Control of hypertension in Italy: results of the "Study on Antihypertensive Treatment in General Practice (STAP)". G Ital Cardiol, 28:760-6.
4. Bhatt DL, Steg PG, Ohman EM, et al. 2006. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA, 295:180-9.
5. Bouma M, Dekker JH, van Eiik JThM, et al. 1999. Metabolic control and morbidity of type 2 diabetic patients in a general practice network. Fam Pract, 16:402-6.
6. Camisasca P, Avanziui F, Alli C, et al. on behalf of the "Studio sul Trattamento Antipertensivo nella Pratica ambulatoriale (STAP)" participants. 2002. Overall cardiovascular risk still ignored in general practice care of hypertension. J Cardiovasc Risk, 9:147-52.
7. Cannon PC, Braunwald E, McCabe CH, et al. 2004. Intensive versus moderate lipid lowering with statins after acute coronary sindromes. N Engl J Med, 350:1495-504,
8. Dunn NR, Bough P. 1996. Standards of care of diabetic patients in a typical English community. Br J Gen Pract, 46:401-5.
9. EUROASPIRE II Study Group. 2001. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J, 22:554-72.
10. European Diabetes Policy Group. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Med, 16:716-30.
11. Ferrario G, Alkhimovitch O, Avanzini F, et al. 2004. Peoples' perception of their overall coronary risk: an Italian experience. Ital Heart J, 5:16-21.
12. Gianpaoli S, Vanuzzo D. 2003. Italian Atlas of Cardiovascular Diseases. 1st ed. Ital Heart J, 4 (Suppl 4):1S-121S.
13. Heart Protecfon Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
14. Hippisley-Cox, Pringle M. 2001. General practice workload implications of the national service framework for coronary heart disease: cross sectional survey. BMJ, 323:269-70.
15. Lloyd-Jones DM, Evans JC, Larson MG, et al. 2002. Treatment and control of hypertension in the community. A prospective analysis. Hypertension, 40:640-6.
16. Moon JC. 2006. Switching statins. Using generic simvastatin as first line could save £2bn over five years in England. BMJ, 332:1344-5.
17. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. 2003. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA, 290:2805-16.
18. Pilotto L, Giaggioli A, Lo Noce C et al. 2004. Il diabete in Italia: un problema di sanità pubblica. Ital Heart J Suppl, 5:480-6.
19. Primatesta P, Brookes M, Poulter NR. 2001. Improved hypertension management and control: results from the heath survey for England 1998. Hypertension, 38:827-32.
20. Primatesta P, Poulter NR. 2000. Lipid concentrations and the use of lipid-lowering drugs: evidence from a national cross-sectional survey. BMJ, 321:1322-5.
21. PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet, 358:1033-41.
22. Roncaglioni MC, Avanzini F, Roccatagliata D, et al. 2004. How general practitioners perceive and grade the cardiovascular risk of their patients. Eur J Cardiovasc Prev Rehabil, 11:233-8.
23. Sleight P, Pouleur H, Zannad F. 2006. Benefits, challenges, and registerability of the polypill. Eur Heart J, 27:1651-6
24. UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
25. UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352:854-65.
26. Wald NJ, Law MR. 2003. A strategy to reduce cardiovascular disease by more than 80%. BMJ, 326:1-6.
27. Wood D, De Backer G, Faergeman O, et al. together with members of the Task Force. 1998. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J, 19:1434-1503.
28. World Health Organization/International Society of Hypertension Guidelines for management of hypertension. 1999. J Hypertens, 17:151-83.